ProMIS Neurosciences Inc. Overview
Pro stress-test →ProMIS Neurosciences is a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). PMN310 has been designed to selectively target toxic amyloid-beta oligomers while sparing plaque, a mechanism the company believes may enable improved efficacy and a differentiated safety profile relative to plaque-directed antibodies.
Strategic Profile
Pro stress-test →The company closed a transformational financing of up to $175 million in Q1 2026, significantly strengthening its balance sheet. The Phase 1b PRECISE-AD trial of PMN310 in early Alzheimer's disease is fully enrolled, with a blinded 6-month interim analysis anticipated in early Q3 2026 and topline data expected in early 2027. Based on the current operating plan, existing cash resources are expected to fund planned operations through 2027, including the completion of the PRECISE-AD trial.
Competitive Landscape
Pro stress-test →ProMIS competes in the Alzheimer's disease antibody therapeutics space against larger biopharmas and specialized neuroscience companies pursuing anti-amyloid strategies. Competitors include Eli Lilly (donanemab), Biogen/Eisai (lecanemab), and smaller clinical-stage programs targeting similar pathways. ProMIS's differentiation centers on selective targeting of toxic oligomers rather than broad plaque clearance, which the company positions as offering potentially superior efficacy-safety profile.
Industry Context
ProMIS Neurosciences Inc. operates in Alzheimer's disease therapeutics.
Key facts
Founded: 2006 · Headquarters: Cambridge, Massachusetts · Employees: N/A · Revenue: N/A · Market cap: N/A